Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis.

Maartje M van de MeebergElwin R VerheijHerma H FidderGerd BoumaAlwin D R HuitemaBas Oldenburg

Published in: Therapeutic drug monitoring (2023)

Fecal (N-acetyl-)5-ASA measurements do not correlate with disease activity, which renders it an unsuitable tool for therapeutic drug monitoring of mesalazine.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
ulcerative colitis
rheumatoid arthritis patients
ankylosing spondylitis
juvenile idiopathic arthritis
human health
risk assessment
climate change